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Supplementary Table S1: Adverse events, grade 3 and 4 only, all attributions
Cohort A Cohort B
  Patients
(% of total 
patients)
Events  
(events per dose  
Sm = 153)
Patients
(% of total 
patients)
Events  
(events per dose  
Sm = 153)
Grade 3
Hematologic 10 (45.5%) 22 (1.0) 13 (59.1%) 43 (1.1)
  Anemia 7 (31.8%) 10 (0.4) 4 (18.2%) 6 (0.15)
  ALC decreased 2 (9.1%) 2 (0.08) 3 (13.6%) 5 (0.13)
  ANC decreased 2 (9.1%) 2 (0.08) 4 (18.2%) 9 (0.23)
  Platelets decreased 3 (13.6%) 7 (0.28) 8 (36.4%) 13 (0.33)
  WBC decreased 0 (0%) 1 (0.04) 5 (22.7%) 9 (0.23)
  INR decreased 0 (0%) 0 (0) 1 (4.5%) 1 (0.03)
 Gastrointestinal 3 (13.6%) 6 (0.24) 4 (18.2%) 6 (0.15)
Constitutional 3 (13.6%) 3 (0.12) 4 (18.2%) 5 (0.13)
Musculoskeletal 4 (18.2%) 3 (0.12) 5 (22.7%) 8 (0.21)
Electrolyte/Metabolic 1 (4.5%) 1 (0.04) 3 (13.6%) 3 (0.08)
Genitourinary 1 (4.5%) 1 (0.04) 0 (0%) 0 (0)
Infection 0 (0%) 0 (0) 1 (4.5%) 1 (0.03)
Dental 0 (0%) 0 (0) 1 (4.5%) 1 (0.03)
Grade 4     
Hematologic 2 (9.1%) 2 (0.08) 3 (13.6%) 3 (0.08)
Grade 5     
Death 1 (4.5%) 1 (0.04) 0 (0%) 0 (0)













(adjusted)Pre Post Pre Post
CD4 24.2–31.2 27.5 29.1 > 0.999 > 0.999 27.6 33.8 0.2031 > 0.999
CD8 15.2–25.1 23.2 29.0 0.0781 0.702 20.4 18.1 0.6523 > 0.999
Treg 2.02–3.11 2.53 2.73 0.3750 > 0.999 2.41 2.54 0.5703 > 0.999
NK 7.6–12.4 8.5 8.6 0.1563 > 0.999 11.1 8.8 0.8203 > 0.999
NK=T 0.61–1.58 1.141 1.178 0.5781 > 0.999 0.779 1.039 0.6523 > 0.999
B Lymphocyte 2.54–6.18 4.00 3.74 0.8125 > 0.999 5.04 4.96 0.6523 > 0.999
cDC 0.047–0.342 0.124 0.154 0.2969 > 0.999 0.128 0.096 0.8203 > 0.999
pDC 0.174–0.407 0.270 0.201 0.2188 > 0.999 0.198 0.259 > 0.999 > 0.999
MDSC 3.26–9.94 5.26 7.44 0.2969 > 0.999 4.60 8.70 0.2031 > 0.999
Abbrevations: Tregs, regulatory T cells; NK, natural killer cells; NK-T, natural killer T cells; cDC, conventional dendritic cells; 
pDC, plasmacytoid dendritic cells; MDSCs, myeloid-derived suppressor cells.
Supplementary Table S2: Flow-cytometry analysis of PBMC immune subsets: 25 markers, 110 subsets
1. CD4: Helper T lymphocytes (28 subsets)
2. CD8: Cytotoxic T lymphocytes (25 subsets)
     Maturation status of T lymphocytes (in CD4 and CD8):
        Naïve: CD45RA+ CCR7+
        Central Memory: CD45RA− CCR7+ 
        Effector Memory: CD45RA− CCR7−
        Terminal (EMRA): CD45RA+ CCR7−
     T lymphocyte markers (in CD4 and CD8):
        CTLA-4: inhibition
        PD-1: activation/inhibition
        PD-L1: activation/cross-inhibition
        TIM-3: inhibition
        ICOS: activation (only on CD4)
3. Tregs:  Regulatory T lymphocytes (CD4+ CD25+ FoxP3+ CD127−) 
(6 subsets)
       CD45RA: Tregs highly expandable in vitro
       CTLA-4: Treg suppression
       ICOS: Treg suppression
       PD-1: activation/inhibition
       PD-L1: cross-inhibition
4. B lymphocytes: CD19+ (3 subsets)
       PD-1: activation/inhibition
       PD-L1: cross-inhibition
5. NK: Natural killer cells (CD56+ CD3−) (20 subsets)
     CD16+ CD56br: Functional intermediate, lytic and cytokine production
     CD16+ CD56dim: Mature NK, cytokine production
     CD16− CD56br: Immature, abundant in human placenta
     CD16− CD56dim: non-lytic, non-cytokine production
     TIM-3: activation
     PD-1: activation/inhibition
     PD-L1: cross-inhibition
6. NK-T: CD56+ CD3+ (4 subsets)
     TIM-3: activation
     PD-1: activation/inhibition
     PD-L1: cross-inhibition
7. cDCs (conventional DCs): CD3−CD56−CD11cbrCD303−CD141− (4 subsets)
8. pDCs (plasmacytoid DCs): CD3−CD56−CD1c−CD303+ (4 subsets)
     Markers of DC activation
        TIM-3: inhibition
        PD-1: activation/inhibition
        PD-L1: cross-inhibition
9. MDSCs:  Myeloid-derived suppressor cells (CD11b+ HLA-DRlow/− CD33+) 
(16 subsets)
     CD14: Common Myeloid Marker (high in monocytes, dim in granulocytes)
     CD15: Granulocyte marker 
     CD68: Monocyte/macrophagemarker
     PD-1: activation/inhibition
     PD-L1: cross-inhibition
Subsets analyzed: 9 standard immune cell subsets, PD-L1 and PD-1 in standard subsets, and 83 additional subsets relating to 
maturation/function.
Supplementary Table S4: Immune cell subsets relating to maturation/function
Sm-153 Alone (n = 7) Sm-153 + PROSTVAC (n = 9)










Pre Post Pre Post
CD4 ICOS+PDL1+ 0.129–0.246 0.166 0.155 0.0469+ > 0.999 0.204 0.124 0.0195 0.468
CD4 CM 0.395–1.1202 0.440 0.636 0.0469+ > 0.999 0.769 1.343 0.0195 0.468
CD8 PDL1+ 0.176–0.305 0.207 0.266 0.5781 > 0.999 0.220 0.170 0.0391 0.897
CD8 PDL1+ EM 0.083–0.186 0.097 0.117 0.8125 > 0.999 0.129 0.072 0.0391 0.897
NK PD1+ CD16–CD56dim 0.040–0.090 0.052 0.121 0.0156 0.288 0.067 0.070 0.4258 > 0.999
MDSC PDL1+ 0.503–2.021 1.469 2.665 0.0156 0.224 0.534 0.891 0.0977 0.999
mMDSC PDL1+ 0.266–1.107 0.421 2.063 0.0156 0.224 0.342 0.592 0.0195+ 0.273
mMDSC PD1+ 0.029–0.151 0.077 0.173 0.0156 0.224 0.054 0.136 0.0742 > 0.999
+Not considered a potentially biologically relevant change, because median post value falls within the interquartile range of pre.
Bold indicates significant P values.
Supplementary Table S5: Antibodies for assessing frequency of peripheral immune cell subsets
Marker Conjugate Clone Company
CTLA4 FITC L3D10 BioLegend
PD1 PE MIH4 BD Bioscience
CCR7 PerCp-Cy5.5 150503 BD Bioscience
PDL1 PE-Cy7 MIH1 BD Bioscience
Tim3 BV421 F38-2E2 BioLegend
CD4 BV605 RPA-T4 BD Bioscience
CD8 APC RPA-T8 BioLegend
CD45RA AF700 HI100 BD Bioscience
CD19 APC-H7 SJ25C1 BD Bioscience
ICOS PerCP-Cy5.5 C398.4A BioLegend
FoxP3 Pac. Blue 206D BioLegend
CD25 APC M-A251 BioLegend
CD127 APC-eF780 eBioRDR5 eBioscience
CD15 FITC HI98 eBioscience
CD68 PerCp-Cy5.5 Y1/82A BioLegend
CD14 V450 M0Pg BD Bioscience
HLA-DR BV605 L243 BioLegend
CD33 APC WM53 BioLegend
CD11b APC-Cy7 ICRF44 BD Bioscience
CD16 FITC 3G8 BD Bioscience
CD303 PerCp-Cy5.5 201A BioLegend
CD11c BV605 3.9 BioLegend
CD56 APC MEM-188 BioLegend
CD141 BV711 (AF700) 1A4 BD Bioscience
CD3 APC Cy7 UCHT1 BioLegend
Supplementary Table S6: Antibodies for assessing antigen-specific responses 
Marker Conjugate Clone Company
TNF PE MAb11 BD Bioscience
CD4 PerCp-Cy5.5 OKT4 BioLegend
IFNγ PE-Cy7 4S.B3 BD Bioscience
IL-2 BV521 MQ1-17H12 BioLegend
CD107a APC H4A3 BD Bioscience
CD8 AF700 RPA-T8 BD Bioscience
